Ultraviolet A1 phototherapy for mycosis fungoides

K Olek-Hrab1, W Silny, A Dańczak-Pazdrowska

  • 1Department of Dermatology, Poznan Medical University of Sciences, Poznan, Poland.

Abstract

Insights

UVA1 phototherapy shows promise for treating early-stage mycosis fungoides (MF), a type of skin lymphoma. This study found complete remission in all patients treated with UVA1, suggesting it may be a safer alternative to PUVA.

Area of Science:

  • Dermatology
  • Oncology
  • Photomedicine

Background:

  • Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma.
  • Current treatments like Psoralen ultraviolet A (PUVA) have risks.
  • UVA1 phototherapy is explored as a potentially safer alternative.

Purpose of the Study:

  • To evaluate the efficacy of UVA1 phototherapy for early-stage MF (T1-T2).

Main Methods:

  • Four patients with early-stage MF received UVA1 treatment.
  • Dosage ranged from 1630-2710 J/cm(2) over 29-40 fractions.
  • Assessment included clinical examination and high-resolution ultrasonography.

Main Results:

  • Complete clinical remission of MF was observed in all treated patients.

Conclusions:

  • UVA1 phototherapy appears to be an effective treatment for early-stage mycosis fungoides.
  • This preliminary study suggests UVA1 as a viable therapeutic option.